Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (273)	9/23/2000 5:26:57 PM
From: BulbaMan	Respond to of 1833

Let's be real conservative and put the downside at $0 and the upside at just $3. Even if you figure the odds are 50/50 for each outcome, KDUS is a good bet at a little over a buck. Of course, I think the downside is much better than $1 as the Axiom stake alone is worth at least that much per KDUS share. And the upside is way over $3, since the KDUS yeast technology and Axiom have the potential to be exceptionally valuable assets. So, why is the KDUS share price hovering just over $1? It seems it's got to be a big seller anxious to unload but not just dumping at any price – although willing to take a $1. My best guess now is that the seller is Bristol and if KDUS had any sense they'd just buy the Bristol shares. Perhaps the Cadus people (sorry, person) are waiting for the patent decision to be final before they take such action. In any case, there should be some kind of announcement soon.